Trial Profile
A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB IN COMBINATION WITH CHEMOTHERAPY FOLLOWED BY MAINTENANCE THERAPY OF AVELUMAB IN COMBINATION WITH THE POLY (ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED OVARIAN CANCER (JAVELIN OVARIAN PARP100)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Apr 2023
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Talazoparib (Primary) ; Bevacizumab; Carboplatin; Paclitaxel
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Sarcoma
- Focus Registrational; Therapeutic Use
- Acronyms JAVELIN OVARIAN PARP 100
- Sponsors Pfizer
- 18 Mar 2022 This trial has been completed in Hungary, according to European Clinical Trials Database.
- 05 Oct 2021 This trial has been completed in Belgium, according to European Clinical Trials Database.
- 19 Feb 2021 Planned End Date changed from 9 Oct 2021 to 28 Nov 2021.